Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort.

Semnani-Azad Z, Johnston LW, Lee C, Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ.

BMJ Open Diabetes Res Care. 2019 Nov 24;7(1):e000825. doi: 10.1136/bmjdrc-2019-000825. eCollection 2019.

2.

X-ray diffraction data and analysis to support phase identification in FeSe and Fe7Se8 epitaxial thin films.

Harris SB, Camata RP.

Data Brief. 2019 Nov 6;27:104778. doi: 10.1016/j.dib.2019.104778. eCollection 2019 Dec.

3.

Oral repeated-dose toxicity studies of BIA 10-2474 in Wistar rat.

Hayes AW, Hardisty JF, Harris SB, Okazaki Y, Weber K.

Regul Toxicol Pharmacol. 2019 Nov 20:104540. doi: 10.1016/j.yrtph.2019.104540. [Epub ahead of print]

4.

Developmental and reproductive toxicity studies of BIA 10-2474.

Harris SB, Hardisty JF, Hayes AW, Weber K.

Regul Toxicol Pharmacol. 2019 Nov 20:104543. doi: 10.1016/j.yrtph.2019.104543. [Epub ahead of print]

5.

The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and β-cell function.

Semnani-Azad Z, Connelly PW, Johnston LW, Retnakaran R, Harris SB, Zinman B, Hanley AJ.

J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz166. doi: 10.1210/clinem/dgz166. [Epub ahead of print]

PMID:
31677389
6.

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators.

Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.

PMID:
31530667
7.

Family Members: The Forgotten Players in the Diabetes Care Team (The TALK-HYPO Study).

Ratzki-Leewing A, Parvaresh Rizi E, Harris SB.

Diabetes Ther. 2019 Dec;10(6):2305-2311. doi: 10.1007/s13300-019-00687-y. Epub 2019 Sep 9.

8.

Living With Hypoglycemia: An Exploration of Patients' Emotions: Qualitative Findings From the InHypo-DM Study, Canada.

Brown JB, Reichert SM, Valliere Y, Webster-Bogaert S, Ratzki-Leewing A, Ryan BL, Harris SB.

Diabetes Spectr. 2019 Aug;32(3):270-276. doi: 10.2337/ds18-0074.

PMID:
31462884
9.

The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort.

Santaren ID, Bazinet RP, Liu Z, Johnston LW, Sievenpiper JL, Giacca A, Retnakaran R, Harris SB, Zinman B, Hanley AJ.

Lipids. 2019 Oct;54(10):617-627. doi: 10.1002/lipd.12185. Epub 2019 Aug 19.

PMID:
31429083
10.

Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41:1672-1680.

Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB.

Diabetes Care. 2019 Aug;42(8):1604. doi: 10.2337/dc19-er08. Epub 2019 Jun 21. No abstract available.

11.

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus.

Frier BM, Ratzki-Leewing A, Harris SB.

Diabetes Obes Metab. 2019 Jul;21(7):1529-1542. doi: 10.1111/dom.13732. Epub 2019 Apr 29. Review.

12.

Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement.

Leiter LA, Cheng AYY, Ekoé JM, Goldenberg RM, Harris SB, Hramiak IM, Khunti K, Lin PJ, Richard JF, Senior PA, Yale JF, Goldin L, Tan MK, Langer A.

Can J Diabetes. 2019 Aug;43(6):384-391. doi: 10.1016/j.jcjd.2018.10.005. Epub 2018 Nov 2.

PMID:
30554985
13.

National Survey of Indigenous primary healthcare capacity and delivery models in Canada: the TransFORmation of IndiGEnous PrimAry HEAlthcare delivery (FORGE AHEAD) community profile survey.

Tompkins JW, Mequanint S, Barre DE, Fournie M, Green ME, Hanley AJ, Hayward MN, Zwarenstein M, Harris SB; FORGE AHEAD Program Team.

BMC Health Serv Res. 2018 Nov 1;18(1):828. doi: 10.1186/s12913-018-3578-8.

14.

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician.

Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS.

Adv Ther. 2018 Nov;35(11):1763-1774. doi: 10.1007/s12325-018-0805-y. Epub 2018 Oct 24. Review.

15.

Computational Predictions and Microwave Plasma Synthesis of Superhard Boron-Carbon Materials.

Baker PA, Catledge SA, Harris SB, Ham KJ, Chen WC, Chen CC, Vohra YK.

Materials (Basel). 2018 Jul 25;11(8). pii: E1279. doi: 10.3390/ma11081279.

16.

A qualitative enquiry of hypoglycemia and the social determinants of health: The InHypo-DM study, Canada.

Brown JB, Reichert SM, Valliere Y, Webster-Bogaert S, Ratzki-Leewing A, Harris SB.

Fam Syst Health. 2018 Dec;36(4):471-481. doi: 10.1037/fsh0000355. Epub 2018 Jul 12.

PMID:
29999342
17.

Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes.

Johnston LW, Liu Z, Retnakaran R, Zinman B, Giacca A, Harris SB, Bazinet RP, Hanley AJ.

J Lipid Res. 2018 Sep;59(9):1751-1762. doi: 10.1194/jlr.P084970. Epub 2018 Jul 9.

18.

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.

Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB.

Diabetes Care. 2018 Aug;41(8):1672-1680. doi: 10.2337/dc18-0168. Epub 2018 Jun 12. Erratum in: Diabetes Care. 2019 Aug;42(8):1604.

PMID:
29895556
19.

Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada.

Ratzki-Leewing A, Harris SB, Mequanint S, Reichert SM, Belle Brown J, Black JE, Ryan BL.

BMJ Open Diabetes Res Care. 2018 Apr 24;6(1):e000503. doi: 10.1136/bmjdrc-2017-000503. eCollection 2018.

20.

Impact of a provincial quality-improvement program on primary health care in Ontario: a population-based controlled before-and-after study.

Green ME, Harris SB, Webster-Bogaert S, Han H, Kotecha J, Kopp A, Ho MM, Birtwhistle RV, Glazier RH.

CMAJ Open. 2017 Apr 6;5(2):E281-E289. doi: 10.9778/cmajo.20160104.

21.

Impact of a primary healthcare quality improvement program on diabetes in Canada: evaluation of the Quality Improvement and Innovation Partnership (QIIP).

Reichert SM, Harris SB, Tompkins JW, Belle-Brown J, Fournie M, Green M, Han H, Kotecha J, Mequanint S, Paquette-Warren J, Roberts S, Russell G, Stewart M, Thind A, Webster-Bogaert S, Birtwhistle R.

BMJ Open Diabetes Res Care. 2017 Aug 29;5(1):e000392. doi: 10.1136/bmjdrc-2017-000392. eCollection 2017.

22.

Association of NEFA composition with insulin sensitivity and beta cell function in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort.

Johnston LW, Harris SB, Retnakaran R, Giacca A, Liu Z, Bazinet RP, Hanley AJ.

Diabetologia. 2018 Apr;61(4):821-830. doi: 10.1007/s00125-017-4534-6. Epub 2017 Dec 24.

PMID:
29275428
23.

TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL.

Yale JF, Berard L, Groleau M, Javadi P, Stewart J, Harris SB.

Can J Diabetes. 2017 Oct;41(5):478-484. doi: 10.1016/j.jcjd.2017.06.007. Epub 2017 Aug 10.

PMID:
28803820
24.

When Insulin Therapy Fails: The Impact of SGLT2 Inhibitors in Patients With Type 2 Diabetes.

Harris SB, Mequanint S, Miller K, Reichert SM, Spaic T.

Diabetes Care. 2017 Oct;40(10):e141-e142. doi: 10.2337/dc17-0744. Epub 2017 Aug 1. No abstract available.

PMID:
28765274
25.

The Diabetes Evaluation Framework for Innovative National Evaluations (DEFINE): Construct and Content Validation Using a Modified Delphi Method.

Paquette-Warren J, Tyler M, Fournie M, Harris SB.

Can J Diabetes. 2017 Jun;41(3):281-296. doi: 10.1016/j.jcjd.2016.10.011. Epub 2017 Mar 6.

26.

Traditional foods and 25(OH)D concentrations in a subarctic First Nations community.

Mansuri S, Badawi A, Kayaniyil S, Cole DE, Harris SB, Mamakeesick M, Wolever T, Gittelsohn J, Maguire JL, Connelly PW, Zinman B, Hanley AJ.

Int J Circumpolar Health. 2016 Jan;75(1):31956. doi: 10.3402/ijch.v75.31956.

27.

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.

Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S.

Diabetes Obes Metab. 2017 Jun;19(6):858-865. doi: 10.1111/dom.12892. Epub 2017 Mar 3.

28.

Call to action: A new path for improving diabetes care for Indigenous peoples, a global review.

Harris SB, Tompkins JW, TeHiwi B.

Diabetes Res Clin Pract. 2017 Jan;123:120-133. doi: 10.1016/j.diabres.2016.11.022. Epub 2016 Dec 5. Review.

29.

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators.

Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7.

30.

The power of two: an update on fixed-dose combinations for type 2 diabetes.

Harris SB.

Expert Rev Clin Pharmacol. 2016 Nov;9(11):1453-1462. doi: 10.1080/17512433.2016.1221758. Epub 2016 Sep 12. Review.

PMID:
27498671
31.

Developing community-driven quality improvement initiatives to enhance chronic disease care in Indigenous communities in Canada: the FORGE AHEAD program protocol.

Naqshbandi Hayward M, Paquette-Warren J, Harris SB; FORGE AHEAD Program Team.

Health Res Policy Syst. 2016 Jul 26;14(1):55. doi: 10.1186/s12961-016-0127-y.

32.

Dietary Patterns and Type 2 Diabetes Mellitus in a First Nations Community.

Reeds J, Mansuri S, Mamakeesick M, Harris SB, Zinman B, Gittelsohn J, Wolever TM, Connelly PW, Hanley A.

Can J Diabetes. 2016 Aug;40(4):304-10. doi: 10.1016/j.jcjd.2016.05.001. Epub 2016 Jun 29.

PMID:
27374251
33.

Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes.

Johnston LW, Harris SB, Retnakaran R, Zinman B, Giacca A, Liu Z, Bazinet RP, Hanley AJ.

J Clin Endocrinol Metab. 2016 Jun;101(6):2536-44. doi: 10.1210/jc.2015-4267. Epub 2016 May 4.

PMID:
27144932
34.

Best Practices for the Prevention and Management of Diabetes and Obesity-Related Chronic Disease among Indigenous Peoples in Canada: A Review.

Rice K, Te Hiwi B, Zwarenstein M, Lavallee B, Barre DE, Harris SB; FORGE AHEAD program team.

Can J Diabetes. 2016 Jun;40(3):216-25. doi: 10.1016/j.jcjd.2015.10.007. Epub 2016 Apr 7. Review.

35.

Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?

Feldman RD, Harris SB, Hegele RA, Pickering JG, Rockwood K.

Can J Cardiol. 2016 May;32(5):598-602. doi: 10.1016/j.cjca.2016.02.002. Epub 2016 Feb 8.

PMID:
27040095
36.

Case study of evaluations that go beyond clinical outcomes to assess quality improvement diabetes programmes using the Diabetes Evaluation Framework for Innovative National Evaluations (DEFINE).

Paquette-Warren J, Harris SB, Naqshbandi Hayward M, Tompkins JW.

J Eval Clin Pract. 2016 Oct;22(5):644-52. doi: 10.1111/jep.12510. Epub 2016 Jan 25.

37.

A dietary two-generation reproductive toxicity study of (2R,4R)-monatin salt in Crl:CD(SD) rats.

Crincoli CM, Brathwaite WA, Casterton PL, Rihner MO, Nikiforov AI, Sloter ED, Harris SB.

Food Chem Toxicol. 2016 May;91:167-80. doi: 10.1016/j.fct.2015.10.015. Epub 2015 Oct 26.

PMID:
26514697
38.

A 90-day dietary study of a (2R,4R)-monatin salt in Beagle dogs.

Crincoli CM, Brathwaite WA, Rihner MO, Nikiforov AI, Harris SB, Greeley MA, Eapen AK.

Food Chem Toxicol. 2016 May;91:181-90. doi: 10.1016/j.fct.2015.08.020. Epub 2015 Aug 31.

PMID:
26334793
39.

Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community.

Mansuri S, Badawi A, Kayaniyil S, Cole DE, Harris SB, Mamakeesick M, Maguire J, Zinman B, Connelly PW, Hanley AJ.

Diabetes Res Clin Pract. 2015 Aug;109(2):440-9. doi: 10.1016/j.diabres.2015.04.017. Epub 2015 Apr 20.

PMID:
25944538
40.

Influence of a quality improvement learning collaborative program on team functioning in primary healthcare.

Kotecha J, Brown JB, Han H, Harris SB, Green M, Russell G, Roberts S, Webster-Bogaert S, Fournie M, Thind A, Reichert SM, Birtwhistle R.

Fam Syst Health. 2015 Sep;33(3):222-30. doi: 10.1037/fsh0000107. Epub 2015 Mar 23.

PMID:
25799255
41.

Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort.

Lee CC, Perkins BA, Kayaniyil S, Harris SB, Retnakaran R, Gerstein HC, Zinman B, Hanley AJ.

Diabetes Care. 2015 May;38(5):793-800. doi: 10.2337/dc14-2585. Epub 2015 Feb 9.

PMID:
25665810
42.

Impact of a quality improvement program on primary healthcare in Canada: a mixed-method evaluation.

Harris SB, Green ME, Brown JB, Roberts S, Russell G, Fournie M, Webster-Bogaert S, Paquette-Warren J, Kotecha J, Han H, Thind A, Stewart M, Reichert S, Tompkins JW, Birtwhistle R.

Health Policy. 2015 Apr;119(4):405-16. doi: 10.1016/j.healthpol.2014.10.019. Epub 2014 Nov 5.

43.

Investments in diabetes strategies: time to evaluate!

Harris SB, Paquette-Warren J.

Can J Diabetes. 2014 Jun;38(3):159-60. doi: 10.1016/j.jcjd.2014.02.029. Epub 2014 May 15. No abstract available.

PMID:
24835516
44.

Type 2 diabetes in Aboriginal peoples.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Harris SB, Bhattacharyya O, Dyck R, Hayward MN, Toth EL.

Can J Diabetes. 2013 Apr;37 Suppl 1:S191-6. doi: 10.1016/j.jcjd.2013.01.046. Epub 2013 Mar 26. No abstract available.

PMID:
24070945
45.

White blood cell subtypes, insulin resistance and β-cell dysfunction in high-risk individuals--the PROMISE cohort.

Lee CT, Harris SB, Retnakaran R, Gerstein HC, Perkins BA, Zinman B, Hanley AJ.

Clin Endocrinol (Oxf). 2014 Oct;81(4):536-41. doi: 10.1111/cen.12390. Epub 2014 Jan 16.

PMID:
24372524
46.

Sandy lake health and diabetes project: a community-based intervention targeting type 2 diabetes and its risk factors in a first nations community.

Kakekagumick KE, Naqshbandi Hayward M, Harris SB, Saksvig B, Gittelsohn J, Manokeesic G, Goodman S, Hanley AJ.

Front Endocrinol (Lausanne). 2013 Nov 12;4:170. doi: 10.3389/fendo.2013.00170. eCollection 2013.

47.
48.

Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the PROMISE cohort study.

Johnston LW, Harris SB, Retnakaran R, Gerstein HC, Zinman B, Hamilton J, Hanley AJ.

Diabetes Care. 2013 Nov;36(11):3599-606. doi: 10.2337/dc13-0254. Epub 2013 Oct 2.

49.

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.

Harris SB, Khunti K, Landin-Olsson M, Galbo-Jørgensen CB, Bøgelund M, Chubb B, Gundgaard J, Evans M.

Patient Prefer Adherence. 2013 Sep 16;7:925-36. doi: 10.2147/PPA.S46805. eCollection 2013.

50.

Type 2 diabetes mellitus management in Canada: is it improving?

Leiter LA, Berard L, Bowering CK, Cheng AY, Dawson KG, Ekoé JM, Fournier C, Goldin L, Harris SB, Lin P, Ransom T, Tan M, Teoh H, Tsuyuki RT, Whitham D, Woo V, Yale JF, Langer A.

Can J Diabetes. 2013 Apr;37(2):82-9. doi: 10.1016/j.jcjd.2013.02.055. Epub 2013 Apr 23. Erratum in: Can J Diabetes. 2013 Aug;37(4):277. Erratum in: Can J Diabetes. 2013 Aug;37(4):277.

PMID:
24070797

Supplemental Content

Loading ...
Support Center